Venetoclax

Evidence Level: L5

Predicted Indications: 6

Venetoclax

Pharmacist Assessment Report

Venetoclax: From Acute Lymphoblastic Leukemia and Richter Syndrome to Hodgkins lymphoma

One-Sentence Summary

Venetoclax is an oral BCL-2 inhibitor. The data compiled for this report list acute lymphoblastic leukemia and Richter syndrome as its original indications. The TxGNN model predicts it may be effective for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with immunoglobulin heavy chain variable-region gene somatic hypermutation. No clinical trials or publications are currently linked to this specific subtype, so the evidence is model prediction plus indirect mechanistic reasoning.

Quick Overview

Item	Content
Original Indication	Acute lymphoblastic/lymphocytic leukemia; Richter syndrome (Canadian label indication text was not available)
Predicted New Indication	CLL/SLL with immunoglobulin heavy chain variable-region gene somatic hypermutation
TxGNN Prediction Score	0.9951
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, venetoclax is a selective BCL-2 inhibitor. It restores apoptosis in cells that depend on BCL-2 for survival.

The predicted indication is a molecular subtype (IGHV-mutated) of CLL/SLL, a disease in which BCL-2 overexpression is a central feature. Venetoclax is already marketed in Canada, and the analysis of this prediction notes that it is established for CLL/SLL in general. This supports a strong mechanistic rationale.

The prediction therefore looks more like a subtype of an established indication than a true repurposing signal. No trials or literature in the compiled data address the IGHV-mutated subtype specifically, so the high score is not independently confirmed.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name
02458055	VENCLEXTA
02458047	VENCLEXTA
02458063	VENCLEXTA
02458039	VENCLEXTA

All four authorizations are valid single-ingredient products. Dosage form and approved indication text were not available.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (BCL-2 inhibitor, BH3 mimetic)
Myelosuppression Risk	Please refer to the package insert warnings and precautions (neutropenia is generally recognised with this class)
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential; tumour lysis syndrome laboratory monitoring (electrolytes, uric acid, creatinine) is generally advised
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction screening completed with 100 interactions in total. The 20 shown in the compiled data include these Major-level interactions:

Aprepitant
Dexamethasone
Clarithromycin
Eliglustat
Rolapitant
Fidaxomicin
Cobicistat
Deferiprone
Samarium (153Sm) lexidronam

Moderate-level interactions include alvimopan, loperamide, cimetidine, naldemedine, metreleptin, miconazole, rifaximin, clotrimazole, troglitazone and deferasirox. Naloxegol is rated Minor.

For other safety information (warnings, contraindications), please refer to the package insert. Label warnings and contraindications were not available in the compiled data.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication has a plausible BCL-2-based mechanism and sits within a disease area where venetoclax is already marketed. However, no trials or publications are linked to this specific subtype. The prediction is therefore not an independent repurposing signal at this stage.

To proceed, the following is needed:

Subtype-specific evidence, such as IGHV-stratified analyses from existing CLL/SLL venetoclax trials
Canadian package insert text (indications, warnings and contraindications) to confirm current labelled use
Detailed mechanism of action data (MOA)
A drug-interaction management plan, especially for strong CYP3A inhibitors, and a monitoring plan for tumour lysis syndrome and myelosuppression
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.